Scholtens A M, Braat A J A T, Tuinenburg A, Meine M, Verberne H J
Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands,
Heart Fail Rev. 2014 Sep;19(5):567-73. doi: 10.1007/s10741-013-9400-0.
Cardiac resynchronization therapy (CRT) is a disease modifying, device-driven treatment that can reduce morbidity and mortality in patients with heart failure. According to the current guidelines, the indication for CRT is only based on QRS duration and functional class of heart failure. However, a substantial amount of patients do not respond to therapy. In addition, CRT is accompanied by significant cost and potential morbidity. It is therefore vital to improve patient selection for CRT to improve patient outcome and minimize therapy-related complications. In this regard, cardiac sympathetic innervation may be of interest. This review addresses the currently available literature, 9 studies with a total number of 225 patients, on CRT and cardiac innervation scintigraphy with (123)I-metaiodobenzylguanidine.
心脏再同步治疗（CRT）是一种改变疾病进程、由设备驱动的治疗方法，可降低心力衰竭患者的发病率和死亡率。根据当前指南，CRT的适应症仅基于QRS波时限和心力衰竭的功能分级。然而，相当一部分患者对治疗无反应。此外，CRT伴随着高昂的成本和潜在的发病率。因此，改善CRT患者的选择对于改善患者预后和尽量减少治疗相关并发症至关重要。在这方面，心脏交感神经支配可能值得关注。本综述涉及目前可用的关于CRT和用（123）I-间碘苄胍进行心脏神经闪烁显像的文献，共9项研究，涉及225例患者。
